Skip to content
  • Clinical Studies
  • Schedule M
  • Stability Studies
  • Pharma GMP
  • Pharma Tips
  • Pharma Books
  • Pharma Validation
  • Pharma Regulatory

SOP Guide for Pharma

The Ultimate Resource for Pharmaceutical SOPs and Best Practices

  • Home
  • SOP Guidelines
    • SOP Development
    • SOP Training
    • SOP Compliance Monitoring
    • SOP Revision Processes
    • Pharmaceutical SOP templates
    • GMP documentation SOP
    • Data integrity SOP pharma
    • Manufacturing SOP pharmaceutical
    • FDA SOP guidance
    • eQMS SOP workflows
  • Job Safety Analysis (JSA)
    • Oral Dosage Forms (Tablets & Capsules)
    • Oral Liquid Dosage Forms (Syrups, Elixirs, Suspensions, Emulsions)
    • Powder and Granule Dosage Forms
    • Topical Dosage Forms (Creams, Ointments, Gels, Lotions, Pastes)
    • Transdermal Dosage Forms (Patches)
  • Standard Test Procedures (STP)
  • GMP Audit Findings
    • Non-Compliance
      • SOP Absence
      • Revision Control
      • Non-Adherence
      • Poor Writing
      • Training Failure
      • Data Integrity Gaps
      • Mismatch Between SOPs and Practice
      • Critical Operations
      • Regulatory Change
      • Emergency Changes
      • Third-Party SOPs
      • Inspection Readiness
      • Deviation Handling
      • CAPA Integration
      • Validation Alignment
      • System Integration
      • Uncontrolled Distribution
      • SOP Implementation Gaps
      • SOP Alignment with Validation
      • Change Control Linkage
  • Toggle search form

Biosimilars: SOP for pH Adjustment of Bulk Protein Solution – V 2.0

Posted on By


Biosimilars: SOP for pH Adjustment of Bulk Protein Solution – V 2.0


Standard Operating Procedure for pH Adjustment of Bulk Protein Solution in Biosimilar Manufacturing

Department Biosimilars
SOP No. SOP/BS/182/2025
Supersedes SOP/BS/182/2022
Page No. Page 1 of 9
Issue Date 04/05/2025
Effective Date 06/05/2025
Review Date 04/05/2026

1. Purpose

To provide a controlled procedure for the adjustment of pH in bulk biosimilar protein solutions after purification, ensuring product quality, stability, and compliance with GMP standards.

2. Scope

This SOP applies to all batches of biosimilar bulk drug substance requiring pH adjustment before formulation or bulk storage within the downstream processing area.

3. Responsibilities

  • Production: Perform pH adjustment as per batch record and record all data in real-time.
  • QC: Provide calibrated pH meters and verify accuracy of final pH values.
  • QA: Review and approve pH adjustment log and ensure batch meets release criteria.

4. Accountability

The Downstream Manufacturing Manager is accountable for the correct execution and documentation of pH adjustment procedures.

5. Procedure

5.1 Preparation

  1. Verify the product-specific target pH range in the BMR (e.g., 6.0–6.5).
  2. Ensure availability of calibrated pH meter, sterile pH probes, and pre-approved acid/base reagents (e.g., 0.1N HCl or 0.1N NaOH).
  3. Confirm volume of protein solution to be adjusted and temperature equilibration (15–25°C recommended).

5.2 pH Measurement

  1. Immerse the pH probe into the sample container with continuous gentle stirring.
  2. Record initial pH and compare against the specification range.

5.3 pH Adjustment

  1. If adjustment is required:
    • Use sterile syringe or peristaltic pump to add 0.1N acid/base dropwise.
    • After each addition, allow thorough mixing (at least 2 minutes) and recheck pH.
    • Continue until pH falls within the specified range.
  2. Record the exact volume of acid/base used in Annexure-1.

5.4 Final Verification

  1. Confirm final pH from three separate readings within 2 minutes.
  2. Ensure homogeneity by sampling from top and bottom of the tank.

5.5 Precautions

  1. Never add acid and base simultaneously.
  2. Use only filtered and validated pH adjusting solutions.
  3. Avoid excessive adjustment that may impact protein stability.

6. Abbreviations

  • pH: Potential of Hydrogen
  • BMR: Batch Manufacturing Record
  • GMP: Good Manufacturing Practice
  • QC: Quality Control

7. Documents

  1. pH Adjustment Log – Annexure-1
  2. Final pH Verification Record – Annexure-2

8. References

  • ICH Q8 – Pharmaceutical Development
  • FDA Guidance on Protein Drug Stability
  • WHO TRS 999 – GMP for Biotherapeutics

9. SOP Version

Version: 2.0

10. Approval Section

Prepared By Checked By Approved By
Signature
Date
Name
Designation
Department

11. Annexures

Annexure-1: pH Adjustment Log

Time Initial pH Reagent Used Volume Added (mL) Adjusted pH Operator
10:00 6.7 0.1N HCl 2.5 6.4 Ajay Verma

Annexure-2: Final pH Verification Record

Sample Point Reading 1 Reading 2 Reading 3 Average pH Result
Top 6.4 6.4 6.3 6.37 Pass
Bottom 6.3 6.4 6.4 6.37 Pass

Revision History:

Revision Date Revision No. Details Reason Approved By
04/05/2025 2.0 Added homogeneity verification and reagent handling steps Audit compliance
See also  Biosimilars: SOP for Monitoring Power Supply Stability - V 2.0
Biosimilars V 2.0 Tags:biosimilar manufacturing SOP, biosimilar process validation SOP, biosimilar quality control procedure, cell line development SOP biosimilars, chromatography SOP biosimilars, cleaning validation SOP for biosimilar equipment, cleanroom SOP for biologics manufacturing, deviation handling SOP in bioprocess, downstream processing SOP, environmental monitoring SOP biosimilars, GMP SOP for biosimilars, host cell protein removal SOP, inline UV monitoring SOP biosimilars, media preparation SOP for biosimilars, protein purification SOP, purification skid calibration SOP, SOP for bioreactor inoculation biosimilars, SOP for biosimilar cell banking, SOP for cell culture in biosimilar production, SOP for chromatography column packing, SOP for ELISA-based clone screening, SOP for endotoxin testing in biologics, SOP for filter sterilization in downstream processing, SOP for glycosylation analysis in biosimilars, SOP for master cell bank, SOP for protein A chromatography steps, SOP for resin qualification in biosimilar purification, SOP for viral clearance in biosimilar production, SOP for working cell bank, upstream processing SOP biosimilars

Post navigation

Previous Post: Gel Manufacturing: SOP for Weighing Micro Quantities of APIs for Gels – V 2.0
Next Post: Elixir Department: SOP for Disposal of Waste After Equipment Cleaning – V 2.0

Standard Operating Procedures V 1.0

  • Aerosols
  • Analytical Method Development
  • Bioequivalence Bioavailability Study
  • Capsule Formulation
  • Clinical Studies
  • Creams
  • Data Integrity
  • Dental Dosage Forms
  • Drug Discovery
  • Environment, Health and Safety
  • Formulation Development
  • Gels
  • Good Distribution Practice
  • Good Warehousing Practices
  • In-Process Control
  • Injectables
  • Liquid Orals
  • Liposome and Emulsion Formulations
  • Lotions
  • Lyophilized Products
  • Maintenance Dept.
  • Medical Devices
  • Metered-Dose Inhaler
  • Microbiology Testing
  • Nanoparticle Formulation
  • Nasal Spray Formulations
  • Nebulizers
  • Ocular (Eye) Dosage Forms
  • Ointments
  • Otic (Ear) Dosage Forms
  • Pharmacovigilance
  • Powder & Granules
  • Purchase Departments
  • Quality Assurance
  • Quality Control
  • Raw Material Stores
  • Regulatory Affairs
  • Tablet Manufacturing
  • Rectal Dosage Forms
  • Transdermal Patches
  • Vaginal Dosage Forms
  • Validations and Qualifications

Read SOPs in your Language:

 - 
Bengali
 - 
bn
English
 - 
en
Gujarati
 - 
gu
Hindi
 - 
hi
Malayalam
 - 
ml
Marathi
 - 
mr
Punjabi
 - 
pa
Tamil
 - 
ta
Telugu
 - 
te

NEW! Revised SOPs – V 2.0

  • Aerosols V 2.0
  • Analytical Method Development V 2.0
  • API Manufacturing V 2.0
  • BA-BE Studies V 2.0
  • Biosimilars V 2.0
  • Capsules V 2.0
  • Creams V 2.0
  • Elixers V 2.0
  • Gels V 2.0
  • Injectables V 2.0
  • Ointments V 2.0
  • Raw Material Warehouse V 2.0
  • Tablet Manufacturing V2.0

New Publication: A must for All.

Copyright © 2025 SOP Guide for Pharma.

Powered by PressBook WordPress theme

Go to mobile version